Manapol powder, which supports optimal cellular communication*, is a pure, premium, 100 percent aloe vera gel extract that is abundant in acemannan, designed to support a healthy immune system.* As the most cutting-edge Glyconutritional product available, Manapol powder additionally may provide gastrointestinal benefits.*For more than 20 years, Manapol powder has been an essential ingredient in other Mannatech products. Mannatech's Advanced Ambrotose ® product and Ambrotose ® complex are among the company's top-selling products containing the aloe gel extract, and are known for their cognitive, immune and gastrointestinal benefits.* Mannatech's technology has been the subject of numerous clinical tests. Currently, 19 studies have been published in peer-reviewed journals, 17 human clinical trials have been published and 12 of those studies were double-blind, placebo-controlled studies — the gold standard for product validation. To date, Mannatech has obtained 125 patents in major global markets to help protect its products and formulas, separating it from other nutritional supplement and direct selling companies. Mannatech's products and formulations are manufactured under the strictest quality controls, with many of Mannatech's core products certified by NSF International. To begin changing your life or the lives of those around you, please visit Mannatech.com. 1 Chemical Abstract Service (CAS) has defined acemannan as requiring a molecular weight of one to two million Daltons. About Mannatech Mannatech, Incorporated, offers a profound wellness experience through a financially rewarding opportunity that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in 25 countries, Mannatech is committed to changing lives. For more information, visit Mannatech.com. Please note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release. *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.